Remove Clinic Remove Disease Remove Presentation
article thumbnail

Penn Medicine to Present Multiple Clinical Trial Results at 2024 ASCO Annual Meeting

Imaging Technology

Schuchter, MD, FASCO , the Madlyn and Leonard Abramson Professor of Clinical Oncology and director of the Tara Miller Melanoma Center at Penn Medicine , is the 2023-2024 ASCO President, and the ASCO Annual Meeting program features more than 200 sessions complementing her Presidential Theme: "The Art and Science of Cancer Care: From Comfort to Cure."

Clinic 111
article thumbnail

Research Showing Genomics- and Image-Guided Subtyping Refines Characterization of Alzheimer’s Disease Presented at SNMMI 2023

Imaging Technology

Based on a novel clustering framework using sparse canonical correlation analysis (SCCA), the integrated approach was successful in identifying four subtypes of Alzheimer’s disease and the top genes associated with each, according to the authors of the study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics.”

Disease 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Aitia to present PET positivity research on Alzheimer's disease at CTAD

AuntMinnie

Aitia is highlighting that data from its Alzheimer's Disease Digital Twins platform will be presented at the upcoming Clinical Trials on Alzheimer's Disease (CTAD), being held from October 24 to 27 in Boston.

Disease 45
article thumbnail

Study on Value of 68Ga-FAPI PET/CT Imaging for Evaluation of Disease Activity in Rheumatoid Arthritis presented during SNMMI 2023

Imaging Technology

christine.book Mon, 06/26/2023 - 12:46 June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease activity in rheumatoid arthritis, according to new research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

Disease 98
article thumbnail

FDA approves donanemab for Alzheimer's disease

AuntMinnie

Food and Drug Administration (FDA) has approved Eli Lilly's drug donanemab (Kisunla) for the treatment of early Alzheimer's disease, including mild cognitive impairment or mild dementia. According to clinical trials, amyloid PET scans showed that donanemab reduced amyloid plaques by up to 84% after 18 months of treatment.

Disease 98
article thumbnail

PET reveals patient responses to new Alzheimer’s disease drug

AuntMinnie

Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Research suggests that the accumulation of these proteins is a continuous process that starts decades before the onset of symptoms.

Disease 119
article thumbnail

Ultrasound model predicts liver disease progress

AuntMinnie

A predictive model combining multiple ultrasonic parameters could discriminate between different liver diseases in a study published March 19 in Radiology. These findings are important for noninvasive assessment of the MAFLD disease process,” the Liu team wrote. The results have been promising when compared to liver biopsy.